Five-year overall survival rate of 19.4% and 18.4% for KEYTRUDA plus chemotherapy in KEYNOTE-189 and KEYNOTE-407, respectively
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Merck( NYSE MRK), known as MSD outside of the United States and Canada, moment blazoned KEYTRUDA, Merck’santi-PD-1 remedy, plus chemotherapy continued to demonstrate a survival benefit and durable responses in two five- time exploratory analyses of vital Phase 3 studies as first- line treatment for metastaticnon-small cell lung cancer( NSCLC)
For cases with metastatic nonsquamous NSCLC, data from KEYNOTE- 189 demonstrated KEYTRUDA plus pemetrexed( ALIMTA ®) and platinum chemotherapy( cisplatin or carboplatin) had a five- time overall survival( zilches) rate of19.4 versus11.3 for chemotherapy alone. The KEYTRUDA- pemetrexed- platinum chemotherapy combination reduced the threat of death by 40( HR = 0.60( 95 CI,0.50-0.72)). At five times, KEYTRUDA plus pemetrexed and cisplatin or carboplatin further than doubled the median zilches compared to chemotherapy alone(22.0 months versus10.6 months);
For cases with metastatic scaled NSCLC, results from KEYNOTE- 407 showed the five- time OS rate for KEYTRUDA plus carboplatin- paclitaxel or nab- paclitaxel was18.4 versus9.7 for chemotherapy alone. KEYTRUDA plus carboplatin- paclitaxel or nab- paclitaxel reduced the threat of death by 29( HR = 0.71( 95 CI,0.59-0.85)) versus chemotherapy alone. The median zilches was17.2 months for the KEYTRUDA plus chemotherapy group versus11.6 months for the chemotherapy group.
KEYTRUDA is the first immunotherapy to demonstrate a sustained five- time survival benefit both in combination with chemotherapy and as monotherapy for the first- line treatment of NSCLC. In addition to NSCLC, five- time survival data for KEYTRUDA have been presented in three other types of cancer, including bladder cancer( KEYNOTE- 045), head and neck cancer( KEYNOTE- 048) and carcinoma( KEYNOTE- 054).
“ The overall survival findings from KEYNOTE- 189 and KEYNOTE- 407 changed the way cases with metastaticnon-small cell lung cancer were treated and established KEYTRUDA plus chemotherapy as a foundational first- line treatment for this ruinous complaint, ” saidDr. Eliav Barr, elderly vice chairman, head of global clinical development and principal medical officer, Merck Research Laboratories. “ Now, with further than five times of follow- up, these studies continue to show emotional survival issues and durable responses for cases entering KEYTRUDA in combination with chemotherapy. In fact, in both studies, of the roughly 55 cases who completed two times of treatment, about 70 were alive at five times. ”
“ Prior to these corner studies, lung cancer had a 10 five- time survival rate, one of the smallest of any cancer, ” saidDr. MarinaC. Garassino, professor of drug, University of Chicago, Hematology/ Oncology, and top investigator for KEYNOTE- 189. “ These results show meaningful advancements in five- time survival for cases entering KEYTRUDA plus chemotherapy and support the important part of these KEYTRUDA- grounded rules as norms of care for metastaticnon-small cell lung cancer. ”
Results from KEYNOTE- 189( abstract# 973MO) and KEYNOTE- 407( abstract# 974MO) are being presented during a mini oral session at the European Society for Medical Oncology( ESMO) Congress 2022. Five- time OS data from KEYNOTE- 024, which estimated KEYTRUDA monotherapy versus chemotherapy for the first- line treatment of cases with metastatic NSCLC whose excrescences expressed PD- L1( excrescence proportion score( TPS) ≥ 50), were presented at ESMO 2020. Five- time OS data from KEYNOTE- 042, which estimated KEYTRUDA monotherapy versus platinum- grounded chemotherapy for the first- line treatment of cases with metastatic NSCLC whose excrescences expressed PD- L1( TPS ≥ 1), were presented at SITC 2021.
As blazoned, data gauging further than 16 different types of cancer are being presented from Merck’s broad oncology portfolio and investigational channel at ESMO Congress 2022.
About lung cancer
Lung cancer is the leading cause of cancer death worldwide. In 2020 alone, there were further than2.2 million new cases and1.8 million deaths from lung cancer encyclopedically. Non-small cell lung cancer is the most common type of lung cancer, counting for about 82 of all cases. In theU.S., the overall five- time survival rate for cases diagnosed with lung cancer is 24, which is a 14 enhancement over the last five times. bettered survival rates are due in part to earlier discovery and webbing, reduction in smoking, advances in individual and surgical procedures as well as the preface of new curatives.
About Merck’s exploration in lung cancer
Merck is advancing exploration aimed at transubstantiating the way lung cancer is treated, with a thing of perfecting issues for cases affected by this deadly complaint. Through nearly 200 clinical trials assessing further than,000 cases around the world, Merck is at the van of lung cancer exploration. In advanced NSCLC, KEYTRUDA has four approvedU.S. suggestions( see suggestions below) and is approved for advanced NSCLC in further than 95 countries. Among Merck’s exploration sweats are trials concentrated on assessing KEYTRUDA in earlier stages of lung cancer as well as relating new combinations and coformulations with KEYTRUDA.
At Merck, known as MSD outside of the United States and Canada, we’re unified around our purpose We use the power of leading- edge wisdom to save and ameliorate lives around the world. For further than 130 times, we’ve brought stopgap to humanity through the development of important drugs and vaccines. We aspire to be the premier exploration- ferocious biopharmaceutical company in the world – and moment, we’re at the van of exploration to deliver innovative health results that advance the forestallment and treatment of conditions in people and creatures. We foster a different and inclusive global pool and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.